Cerity Partners LLC acquired a new position in Organon & Co. (NYSE:OGN – Get Rating) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 7,889 shares of the company’s stock, valued at approximately $267,000.
Several other large investors have also recently made changes to their positions in OGN. Crestwood Advisors Group LLC acquired a new stake in Organon & Co. during the 2nd quarter worth approximately $201,000. Wealthsource Partners LLC acquired a new stake in shares of Organon & Co. in the 1st quarter valued at $314,000. Banque Pictet & Cie SA acquired a new stake in shares of Organon & Co. in the 2nd quarter valued at $1,712,000. Treasurer of the State of North Carolina raised its holdings in shares of Organon & Co. by 15.0% in the 2nd quarter. Treasurer of the State of North Carolina now owns 107,500 shares of the company’s stock valued at $3,628,000 after purchasing an additional 14,046 shares in the last quarter. Finally, ING Groep NV acquired a new stake in shares of Organon & Co. in the 2nd quarter valued at $254,000. 76.28% of the stock is currently owned by institutional investors and hedge funds.
Organon & Co. Price Performance
NYSE OGN opened at $24.72 on Tuesday. The firm’s fifty day moving average price is $25.20 and its 200 day moving average price is $30.42. The company has a market capitalization of $6.29 billion, a price-to-earnings ratio of 6.17 and a beta of 0.87. Organon & Co. has a 12 month low of $22.88 and a 12 month high of $39.47.
Organon & Co. Announces Dividend
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on OGN shares. Bank of America lowered shares of Organon & Co. from a “neutral” rating to an “underperform” rating and set a $25.00 price objective on the stock. in a report on Friday, October 14th. Morgan Stanley reduced their price objective on shares of Organon & Co. from $27.00 to $24.00 and set an “equal weight” rating on the stock in a report on Friday, November 4th. Finally, Piper Sandler raised shares of Organon & Co. from a “neutral” rating to an “overweight” rating and dropped their target price for the company from $37.00 to $34.00 in a research report on Tuesday, September 6th.
Organon & Co. Company Profile
Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
- Get a free copy of the StockNews.com research report on Organon & Co. (OGN)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Is Ardelyx is A Buy After Slip in Early 2022
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.